Master Services Agreement for Drug Product Development and Manufacturing (the “Agreement”)Master Services Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)
WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;
MANUFACTURING RIGHTS AGREEMENTManufacturing Rights Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • Delaware
This MANUFACTURING RIGHTS AGREEMENT (this “Agreement”), effective as of the Effective Date, is entered into by and between Vaxcyte, Inc., a Delaware corporation (“Vaxcyte”) and Sutro Biopharma, Inc., a Delaware corporation (“Sutro”) (each of Vaxcyte and Sutro, a “Party,” and collectively, the “Parties”).
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)
This first amendment to the License Agreement ("Amendment No. 1") is made by and between Sutrovax, Inc., having an address at 353 Hatch Drive, Foster City, California 94404 ("LICENSEE") and The Regents of the University of California, a California corporation having its administrative offices at 1111 Franklin Street, Oakland, California 94607 ("UNIVERSITY"), as represented by its San Diego campus having an address at University of California San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093.
pre-commercial Services and Commercial Manufacturing Supply AgreementPre-Commercial Services and Commercial Manufacturing Supply Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)
WHEREAS, Vaxcyte US is, and Vaxcyte is intended to be, engaged in the development and research of certain products and requires assistance in the manufacture of certain products;
FIRST AMENDMENT TO LEASELease Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of October 17, 2023, and effective as of January 1, 2023 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and VAXCYTE, INC., a Delaware corporation (“Tenant”).
